Literature DB >> 18545986

Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.

Kristin B Dupre1, Karen L Eskow, Aimee Steiniger, Anna Klioueva, Giselle E Negron, Lydia Lormand, John Y Park, Christopher Bishop.   

Abstract

RATIONALE: Serotonin 1A receptor (5-HT1AR) agonists reduce L-DOPA-induced dyskinesia and enhance motor function in experimental and clinical investigations of Parkinson's disease (PD). While the mechanism(s) by which these effects occur are unclear, recent research suggests that modulation of glutamate neurotransmission contributes.
OBJECTIVE: To further delineate the relationship between 5-HT1A receptors and glutamate, the current study examined the effects of the 5-HT1AR agonist, +/-8-OH-DPAT and the N-methyl-D-aspartic acid receptor (NMDAR) antagonist, MK-801, on L-DOPA-induced motor behavior.
MATERIALS AND METHODS: Unilateral 6-hydroxydopamine lesioned male Sprague-Dawley rats were rendered dyskinetic with 1 week of daily L-DOPA (12 mg/kg, i.p.) + benserazide (15 mg/kg, i.p.). On test days, one group of rats received pretreatments of: +/-8-OH-DPAT (0, 0.03, 0.1, 0.3 mg/kg, i.p.) or MK-801 (0, 0.03, 0.1, 0.3 mg/kg, i.p.). A second group was administered combined +/-8-OH-DPAT (0, 0.03 or 0.1 mg/kg, i.p.) + MK-801 (0, 0.1 mg/kg, i.p.). Pretreatments were followed by L-DOPA administration, after which, abnormal involuntary movements (AIMs) and rotations were monitored. To investigate effects on motor performance, subthreshold doses of +/-8-OH-DPAT (0.03 mg/kg, i.p.) + MK-801 (0.1 mg/kg, i.p.) were administered to L-DOPA-naïve hemiparkinsonian rats before the forepaw adjusting steps test.
RESULTS: Individually, both +/-8-OH-DPAT and MK-801 dose-dependently decreased L-DOPA-induced AIMs without affecting rotations. Combined subthreshold doses of +/-8-OH-DPAT+MK-801 reduced L-DOPA-induced AIMs and potently enhanced contralateral rotations without altering L-DOPA-induced motor improvements.
CONCLUSIONS: The current results indicate a functional interaction between 5-HT1AR and NMDAR that may improve pharmacological treatment of PD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545986     DOI: 10.1007/s00213-008-1135-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  56 in total

1.  Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

Authors:  C Warren Olanow; Philippe Damier; Christopher G Goetz; Thomas Mueller; John Nutt; Olivier Rascol; Alexandru Serbanescu; Frieda Deckers; Hermann Russ
Journal:  Clin Neuropharmacol       Date:  2004 Mar-Apr       Impact factor: 1.592

2.  A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation.

Authors:  I C Kilpatrick; M W Jones; O T Phillipson
Journal:  J Neurochem       Date:  1986-06       Impact factor: 5.372

3.  Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys.

Authors:  D Frechilla; A Cobreros; L Saldise; R Moratalla; R Insausti; M Luquin; J Del Río
Journal:  Synapse       Date:  2001-03-15       Impact factor: 2.562

4.  Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions.

Authors:  Kazuo Matsubara; Keiko Shimizu; Manabu Suno; Kento Ogawa; Toshio Awaya; Takehiro Yamada; Toshihiro Noda; Machiko Satomi; Ko-ichi Ohtaki; Kaoru Chiba; Yoshikazu Tasaki; Hiroshi Shiono
Journal:  Brain Res       Date:  2006-08-01       Impact factor: 3.252

5.  In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.

Authors:  Mahmoud M Iravani; Kayhan Tayarani-Binazir; Wing B Chu; Michael J Jackson; Peter Jenner
Journal:  J Pharmacol Exp Ther       Date:  2006-09-07       Impact factor: 4.030

6.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.

Authors:  M Olsson; G Nikkhah; C Bentlage; A Björklund
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

7.  Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.

Authors:  Frédéric Calon; Ali H Rajput; Oleh Hornykiewicz; Paul J Bédard; Thérèse Di Paolo
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

8.  Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease.

Authors:  S Robelet; C Melon; B Guillet; P Salin; L Kerkerian-Le Goff
Journal:  Eur J Neurosci       Date:  2004-09       Impact factor: 3.386

9.  NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.

Authors:  R H Wessell; S M Ahmed; F S Menniti; G L Dunbar; T N Chase; J D Oh
Journal:  Neuropharmacology       Date:  2004-08       Impact factor: 5.250

Review 10.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

Authors:  Penelope J Hallett; David G Standaert
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

View more
  19 in total

1.  Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.

Authors:  Corinne Y Ostock; Kristin B Dupre; Karen L Eskow Jaunarajs; Hannah Walters; Jessica George; David Krolewski; Paul D Walker; Christopher Bishop
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

Review 2.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

3.  Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Karen L Eskow Jaunarajs; Thomas Button; Lisa M Savage; William Wolf; Christopher Bishop
Journal:  Exp Neurol       Date:  2011-02-22       Impact factor: 5.330

4.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

5.  Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

Authors:  Saki Shimizu; Yukihiro Ohno
Journal:  Aging Dis       Date:  2012-11-29       Impact factor: 6.745

6.  Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.

Authors:  Kristin B Dupre; Karen L Eskow; Christopher J Barnum; Christopher Bishop
Journal:  Neuropharmacology       Date:  2008-09-10       Impact factor: 5.250

7.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

Review 8.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

9.  Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.

Authors:  Melanie A Paquette; Alex A Martinez; Teresa Macheda; Charles K Meshul; Steven W Johnson; S Paul Berger; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2012-08-03       Impact factor: 3.386

10.  MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.

Authors:  Melanie A Paquette; Akari M Anderson; Jason R Lewis; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Neuropharmacology       Date:  2010-01-14       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.